Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04446286

Acronym

ECMO-SL-CoV-2

Enrollment

Registered

2020-06-24

Start date

2020-06-18

Completion date

2020-08-18

Last updated

2021-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Keywords

Respiratory Distress Syndrome, SARS-CoV-2, Extracorporeal membrane oxygenation, ECMO-VV, ECMO-VA, Veno-venous ECMO

Brief summary

Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patient over the age of 18; * Diagnostic COVID-19 by RT-PCR; * Hospitalisation in resuscitation for the management of complications related to COVID-19 * Implanted ECMO-VV or VA during hospitalisation; * Patient agreeing to participate in the study

Exclusion criteria

* Sujet who has expressed opposition to participating in the study. * Sujet under guardianship or trusteeship * Sujet under safeguard of justice

Design outcomes

Primary

Measure	Time frame
Retrospective description of effect of the ECMO-VV or ECMO-VA in the management of severe ARDS refractory in patients of the Strasbourg and Louvain centres with covid-19	files analysed retrospectily from March 1st, 2020 to August 1st, 2020 will be examined

Countries

France

Outcome results